Wisepill Technologies, vendor of medication adherence management solutions, and Internet of Things (IoT) company Aeris announced this week that they are collaborating to help pharmaceutical businesses and healthcare organizations improve medication management for their patients through IoT-enabled smart pillboxes.
The Wisepill electronic pillbox monitors patient adherence and provides instant feedback via cellular and IoT technologies. Unlike many reminder systems on the market that nag users to take their medicine, the Wisepill system was created to remind users only when they forget.
Wisepill has been used by patients with tuberculosis, human immunodeficiency virus (HIV), epilepsy, osteoporosis, chronic heart conditions, diabetes, leukemia, asthma, attention deficit hyperactive disorder (ADHD), and hepatitis C in more than 20 countries. The Family Health International chose Wisepill for its Truvada clinical trials. This was the first time that anti-retro viral drugs were used as a pre-exposure prophylaxis treatment for high-risk HIV patients.
Wisepill Technologies is the creator of the Wisepill dispenser, a pillbox with a global systems for mobile communications (GSM) chip that uses a mobile phone and IoT technologies enabled by Aeris to provide real-time medication management solutions.
Aeris IoT Connectivity services deliver flexible, next-generation connectivity and platform solutions. The platform can enable IoT connectivity to maximize the value and profitability of the application, while managing the underlying complexity. Aeris focuses on delivering not just network access, but specialized connectivity and platform solutions.
Wisepill was founded in 2007 by Lloyd and Ricci Marshall to tackle the challenging problem of medication non-adherence in both developed and developing countries. The Wisepill dispenser was designed so that it would be easy to use. A number of independent user surveys have shown that people benefit from using the dispenser and appreciate the support they receive via the service and reminders.
epilepsy, osteoporosis, chronic heart conditions, diabetes, leukemia, asthma, attention deficit hyperactive disorder (ADHD), and hepatitis C in more than 20 countries. The Family Health International chose Wisepill for its Truvada clinical trials. This was the first time that anti-retro viral drugs were used as a pre-exposure prophylaxis treatment for high-risk HIV patients.
The Wisepill system also has been used by research organizations and universities to monitor adherence for research purposes. Wisepill has worked with Massachusetts General Hospital and the Harvard Initiative for Global Health to adapt the technology to work well in a rural environment where cellular networks are not always reliable.
